Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposomal Bupivicaine (bupivacaine liposome) (Pacira BioSciences, 0432ad)
- Development stage
- Approved
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Percutaneous, Parenteral
01
Overview
Liposomal bupivacaine is an amide-type local anesthetic encapsulated within multivesicular liposomes (DepoFoam technology) designed for prolonged postsurgical analgesia. Unlike standard bupivacaine hydrochloride, which has a relatively short duration of action, the liposomal formulation allows for a slow, controlled release of the drug, extending pain relief for up to 72 hours. Its mechanism of action involves the reversible blockade of voltage-gated sodium channels on nerve membranes, which inhibits the ionic flux required for the initiation and conduction of nerve impulses. Developed by Pacira BioSciences, it is FDA-approved for various applications including local infiltration, interscalene brachial plexus nerve block, and sciatic nerve block to manage postoperative pain, thereby potentially reducing the need for systemic opioids.
- Brand names
- Exparel
- Other names
- Liposomal bupivacaineBupivacaine liposome injectable suspension
02
Targets
KCNA5 (Ultra-rapid delayed rectifier potassium channel)KCNK5 (Potassium channel subfamily K member 5)NMDAR (Glutamate receptor ionotropic, NMDA)SCN5A (Sodium channel protein type 5 subunit alpha)NaV alpha (Voltage-gated sodium channel alpha subunit family)
Beyond the preview
Go deeper on Liposomal Bupivicaine (bupivacaine liposome) (Pacira BioSciences, 0432ad).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liposomal Bupivicaine (bupivacaine liposome) (Pacira BioSciences, 0432ad).